Zolgensma and Seven Other Products Get CHMP Thumbs Up
Executive Summary
Zolgensma should receive a conditional approval, says the European Medicines Agency’s drug evaluation committee, the CHMP.
You may also be interested in...
Stemline And Karyopharm Want More Time At EMA
A number of companies with marketing applications at the later stages of the EU review process are seeking extra time to address remaining concerns the European Medicines Agency’s drug evaluation committee, the CHMP, has about their filings.
Triple Combination Therapy First For Asthma Among Eight Wins At EMA
Novartis is among a number of companies that this week moved closer to marketing new products across the EU. D&A Pharma has again failed to convince the European Medicines Agency that its alcohol dependence treatment should be approved.
Crunch Time At EMA For Luspatercept And Glasdegib
Eight new marketing applications including ones from BMS/Acceleron Pharma and Pfizer are up for an opinion at the April meeting of the European Medicines Agency’s drug evaluation committee, the CHMP.